↓ Skip to main content

Anvirzel™ in combination with cisplatin in breast, colon, lung, prostate, melanoma and pancreatic cancer cell lines

Overview of attention for article published in BMC Pharmacology and Toxicology, March 2013
Altmetric Badge

About this Attention Score

  • Good Attention Score compared to outputs of the same age (67th percentile)

Mentioned by

twitter
3 tweeters
facebook
1 Facebook page

Citations

dimensions_citation
24 Dimensions

Readers on

mendeley
46 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Anvirzel™ in combination with cisplatin in breast, colon, lung, prostate, melanoma and pancreatic cancer cell lines
Published in
BMC Pharmacology and Toxicology, March 2013
DOI 10.1186/2050-6511-14-18
Pubmed ID
Authors

Panagiotis Apostolou, Maria Toloudi, Marina Chatziioannou, Eleni Ioannou, Dennis R Knocke, Joe Nester, Dimitrios Komiotis, Ioannis Papasotiriou

Abstract

BACKGROUND: Platinum derivatives are used widely for the treatment of many cancers. However, the toxicity that is observed makes imperative the need for new drugs, or new combinations. AnvirzelTM is an extract which has been demonstrated with experimental data that displays anticancer activity. The aim of the present study is to determine whether the combination of Cisplatin and AnvirzelTM has a synergistic effect against different types of cancer.Materials and methods: To measure the efficacy of treatment with Cisplatin and AnvirzelTM, methyl-tetrazolium dye (MTT) chemosensitivity assays were used incorporating established human cancer cell lines. Measurements were performed in triplicates, three times, using different incubation times and different concentrations of the two formulations in combination or on their own. t-test was used for statistical analysis. RESULTS: In the majority of the cell lines tested, lower concentrations of AnvirzelTM induced a synergistic effect when combined with low concentrations of Cisplatin after an incubation period of 48 to 72 h. The combination of AnvirzelTM/Cisplatin showed anti-proliferative effects against a wide range of tumours. CONCLUSION: The results showed that the combination of AnvirzelTM and Cisplatin is more effective than monotherapy, even when administered at low concentrations; thus, undesirable toxic effects can be avoided.

Twitter Demographics

The data shown below were collected from the profiles of 3 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 46 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
United States 1 2%
Greece 1 2%
Kenya 1 2%
Unknown 43 93%

Demographic breakdown

Readers by professional status Count As %
Student > Bachelor 12 26%
Student > Master 8 17%
Student > Ph. D. Student 5 11%
Researcher 4 9%
Student > Postgraduate 3 7%
Other 4 9%
Unknown 10 22%
Readers by discipline Count As %
Biochemistry, Genetics and Molecular Biology 12 26%
Agricultural and Biological Sciences 11 24%
Chemistry 4 9%
Engineering 2 4%
Medicine and Dentistry 2 4%
Other 4 9%
Unknown 11 24%

Attention Score in Context

This research output has an Altmetric Attention Score of 4. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 19 August 2020.
All research outputs
#6,582,102
of 20,991,427 outputs
Outputs from BMC Pharmacology and Toxicology
#124
of 400 outputs
Outputs of similar age
#59,072
of 188,098 outputs
Outputs of similar age from BMC Pharmacology and Toxicology
#1
of 1 outputs
Altmetric has tracked 20,991,427 research outputs across all sources so far. This one has received more attention than most of these and is in the 68th percentile.
So far Altmetric has tracked 400 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 5.4. This one has gotten more attention than average, scoring higher than 68% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 188,098 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 67% of its contemporaries.
We're also able to compare this research output to 1 others from the same source and published within six weeks on either side of this one. This one has scored higher than all of them